Tuberculosis (TB) and human immunodeficiency virus (HIV) represent a significant burden
of disease on a global scale. Despite improvements in the global epidemic status, largely …

The alarming increase in antimicrobial resistance in the last decades has prompted the
search for alternatives. Antimicrobial peptides (AMPs) represent a heterogeneous class of …

The spread of multi-drug resistance and the slow pace at which antibiotics come onto the
market are undermining our ability to treat human infections, leading to high mortality rates …

Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis,
has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around …

Infectious diseases are an important growing public health problem, which perspective has
worsened due to the increasing number of drug-resistant strains in the last few years …

The term 'antimicrobial peptides' refers to a large number of peptides first characterized on
the basis of their antibiotic and antifungal activities. In addition to their role as endogenous …

Antimicrobial peptides (AMPs) have attracted extensive research attention worldwide.
Harnessing and creating AMPs synthetically has the potential to help overcome increasing …

Antimicrobial peptides/proteins are ancient and naturallyoccurring antibiotics in innate
immune responses in a variety of organisms. Additionally, these peptides have been …

Successful in vivo infection following pathogen entry requires the evasion and subversion of
multiple immunological barriers. Antimicrobial peptides (AMPs) are one of the first immune …

The treatment of infectious diseases is increasingly prone to failure due to the rapid spread
of antibiotic-resistant pathogens. Antimicrobial peptides (AMPs) are natural components of …